LMNA and COVID-19: These findings are therefore a warning, in our opinion, that patients with LMNA p.R349W mutation (and likely many other LMNA mutations including those causing familial partial lipodysrophy), should be considered at increased risk of late onset cardiological manifestations of COVID-19 and therefore undergo vigilant follow-up after SARS-CoV-2 infection.